Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key…
Browsing: Liver
iFrame is not supported! NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study…
NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study The NRG/RTOG 1112 (NRG…
Hepion Pharmaceuticals Inc Lead Therapy, Rencofilstat Approved for FDA Orphan Drug Designation  Some of the leading causes of liver…
Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by…
Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, Hepatologist, Transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by…
Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas…
Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas…
Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland…
Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German…
Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German…
Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division…
Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division…
Mandana Emamzadeh, Ph.D., Pharma Analyst at GlobalData speaks about New Standard Of Care In Hepatocellular Carcinoma Shifts The Treatment Paradigm…
Professor Tony Hunter, Ph.D., and Rajasree Kalagiri, Ph.D. of the Salk Institute for Biological Studies discuss the article Salk team…
Eric J. Lehrer MD, MS from Icahn School of Medicine at Mount Sinai speaks about the ASTRO Abstract 3419 The…
Zarnie Lwin, MD Royal Brisbane, and Women’s Hospital, University of Queensland discusses the ESMO abstract LBA41 – LEAP-005: Phase II…
John Bridgewater, MD, Ph.D., Medical Oncologist discusses ESMO abstracts Efficacy and Safety of Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2…
Marwan Fakih, MD at City of Hope discusses an abstract from AACR20 entitled Efficacy and Safety of Pembrolizumab in Previously…
Christopher Jakubowski, MD The Johns Hopkins discusses an abstract from The Journal of Clinical Oncology entitled Response to Crizotinib in…
Bruno Sangro, MD, Ph.D. at Clinica Universidad de Navarro discusses The unmet need in HCC patients, the ADP-A2AFP complete response…
Robin Kate Kelley, MD of the University of California, San Francisco discusses the most effective way to combined a CTL4…
Robin Kate Kelley, MD gives an overview of a presentation from ASCO 2020 entitled Efficacy, tolerability, and biologic activity of…
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311…
Timothy Heuer, Ph.D., twoXAR Pharmaceuticals discusses Presents Positive Preclinical Safety & Efficacy Data for its Novel Investigational Cancer Treatment TXR-311…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Studies show that proton therapy compared to traditional radiation increases overall survival in patients with inoperable liver cancer and recognizes…
Michael Buckstein, MD of Mount Sinai answers commonly asked questions by his colleagues: are you overtreating the patients? What is…
Michael Buckstein, MD of Mount Sinai explains the Phase II trial using combination of TACE and SBRT for unresectable single…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains MSK Looked at Transcriptomic Signature | Outcomes For Patients Undergoing Antigenic…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Whether TKI & I-O Combinations are superior | Subgroups That Should…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Assign Genomic & Transcriptomic Features | To Treatment Subtypes to See…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Understanding Tumor Microenvironment | Using Omics Platforms to Assign Treatment at…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Axitinib Titration Post-I-O Therapy | Change Dose to Maximize Quality of…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Axitinib Titration Post-I-O Therapy | Change Dose to Maximize Quality of…